# Jain Dataset - ELISA-based Fragments (SSOT)
# Source: test_datasets/jain/processed/jain_with_private_elisa_FULL.csv
# Labeling: ELISA flags (0→specific, 1-3→mild, ≥4→non-specific)
# Distribution: 94 specific / 22 non-specific / 21 mild
# Generated: 2025-11-06
# Script: preprocessing/jain/step3_extract_fragments.py
id,sequence,label,elisa_flags,source
abituzumab,GYTFSSFWINPRSGYTASFLGRGAMDY,0.0,0,jain2017_pnas
abrilumab,GYTLSDLSFDPQDGETATGSSSSWFDP,0.0,0,jain2017_pnas
adalimumab,GFTFDDYAITWNSGHIAKVSYLSTASSLDY,0.0,0,jain2017_pnas
alemtuzumab,GFTFTDFYIRDKAKGYTTAREGHTAAPFDY,0.0,0,jain2017_pnas
alirocumab,GFTFNNYAISGSGGTTAKDSNWGNFDL,0.0,0,jain2017_pnas
anifrolumab,GYIFTNYWIYPGDSDIARHDIEGFDY,0.0,0,jain2017_pnas
atezolizumab,GFTFSDSWISPYGGSTARRHWPGGFDY,0.0,0,jain2017_pnas
bapineuzumab,GFTFSNYGIRSGGGRTVRYDHYSGSSDY,0.0,0,jain2017_pnas
basiliximab,GYSFTRYWIYPGNSDTSRDYGYYFDF,0.0,0,jain2017_pnas
bavituximab,GYSFTGYNIDPYYGDTVKGGYYGHWYFDV,0.0,0,jain2017_pnas
belimumab,GGTFNNNAIIPMFGTAARSRDLLLFPHHALSP,1.0,6,jain2017_pnas
benralizumab,GYTFTSYVINPYNDGTGREGIRYYGLLGDY,0.0,0,jain2017_pnas
bevacizumab,GYTFTNYGINTYTGEPAKYPHYYGSSHWYFDV,0.0,0,jain2017_pnas
bimagrumab,GYTFTSSYINPVSGSTARGGWFDY,0.0,0,jain2017_pnas
blosozumab,GFPIKDTFSDPEIGDTATGDTTYKFDF,1.0,6,jain2017_pnas
bococizumab,GYTFTSYYISPFGGRTARERPLYASDL,1.0,6,jain2017_pnas
brentuximab,GYTFTDYYIYPGSGNTANYGNYWFAY,,3,jain2017_pnas
briakinumab,GFTFSSYGIRYDGSNKKTHGSHDN,1.0,4,jain2017_pnas
brodalumab,GYTFTRYGISTYSGNTARRQLYFDY,,1,jain2017_pnas
canakinumab,GFTFSVYGIWYDGDNQARDLRTGPFDY,0.0,0,jain2017_pnas
carlumab,GGTFSSYGIIPIFGTAARYDGIYGELDF,1.0,4,jain2017_pnas
certolizumab,GYVFTDYGINTYIGEPARGYRSYAMDY,0.0,0,jain2017_pnas
cetuximab,GFSLTNYGIWSGGNTARALTYYDYEFAY,0.0,0,jain2017_pnas
cixutumumab,GGTFSSYAIIPIFGTAARAPLRFLEWSTQDHYYYYYMDV,1.0,6,jain2017_pnas
clazakizumab,GFSLSNYYIYGSDETARDDSSDWDAKFNL,0.0,0,jain2017_pnas
codrituzumab,GYTFTDYELDPKTGDTTRFYSYTY,1.0,6,jain2017_pnas
crenezumab,GFTFSSYGINSNGGSTASGDY,0.0,0,jain2017_pnas
dacetuzumab,GYSFTGYYVIPNAGGTAREGIYW,0.0,0,jain2017_pnas
daclizumab,GYTFTSYRINPSTGYTARGGGVFDY,,1,jain2017_pnas
dalotuzumab,GYSITGGYLISYDGTNARYGRVFFDY,1.0,5,jain2017_pnas
daratumumab,GFTFNSFAISGSGGGTAKDKILWFGEPVFDY,0.0,0,jain2017_pnas
denosumab,GFTFSSYAITGSGGSTAKDPGTTVIMSWFDP,1.0,5,jain2017_pnas
dinutuximab,GSSFTGYNIDPYYGGTVSGMEY,0.0,0,jain2017_pnas
drozitumab,GFTFDDYAINWQGGSTAKILGAGRGWYFDY,0.0,0,jain2017_pnas
duligotuzumab,GFTLSGDWISAAGGYTARESRVSFEAAMDY,1.0,6,jain2017_pnas
dupilumab,GFTFRDYAISGSGGNTAKDRLSITIRPRYYGLDV,1.0,5,jain2017_pnas
eculizumab,GYIFSNYWILPGSGSTARYFFGSSPNWYFDV,0.0,0,jain2017_pnas
efalizumab,GYSFTGHWIHPSDSETARGIYFYGTTYFDY,0.0,0,jain2017_pnas
eldelumab,GFTFSNNGIWFDGMNKAREGDGSGIYYYYGMDV,0.0,0,jain2017_pnas
elotuzumab,GFDFSRYWINPDSSTIARPDGNYWYFDV,0.0,0,jain2017_pnas
emibetuzumab,GYTFTDYYVNPNRRGTARANWLDY,1.0,6,jain2017_pnas
enokizumab,GGTFSYYWILPGSGTTARADYYGSDYVKFDY,0.0,0,jain2017_pnas
epratuzumab,GYTFTSYWINPRNDYTARRDITTFY,,1,jain2017_pnas
etrolizumab,GFFITNNYISYSGSTARTGSSGYFDF,,2,jain2017_pnas
evolocumab,GYTLTSYGVSFYNGNTARGYGMDV,,2,jain2017_pnas
farletuzumab,GFTFSGYGISSGGSYTARHGDDPAWFAY,0.0,0,jain2017_pnas
fasinumab,GFTLTELSFDPEDGETSTIFGVVTNFDN,0.0,0,jain2017_pnas
fezakinumab,GYTFTNYYINPYTGSAAREPEKFDSDDSDV,0.0,0,jain2017_pnas
ficlatuzumab,GYTFTTYWINPTNGHTARNYVGSIFDY,0.0,0,jain2017_pnas
figitumumab,GFTFSSYAISGSGGTTAKDLGWSDSYYYYYGMDV,,3,jain2017_pnas
fletikumab,GYTFTNDIINAGYGNTAREPLWFGESSPHDYYGMDV,0.0,0,jain2017_pnas
foralumab,GFKFSGYGIWYDGSKKARQMGYWHFDL,,2,jain2017_pnas
fresolimumab,GYTFSSNVVIPIVDIAASTLGLVLDAMDY,0.0,0,jain2017_pnas
fulranumab,GFTLRSYSISRSSHTIARVYSSGWHVSDYFDY,,1,jain2017_pnas
galiximab,GGSISGGYGFYSSSGNTVRDRLFSVVGMVYNNWFDV,0.0,0,jain2017_pnas
ganitumab,GGSISSSNWIYHSGSTARWTGRTDAFDI,0.0,0,jain2017_pnas
gantenerumab,GFTFSSYAINASGTRTARGKGNTHKPYGYVRYFDV,1.0,6,jain2017_pnas
gemtuzumab,GYTITDSNIYPYNGGTVNGNPWLAY,0.0,0,jain2017_pnas
gevokizumab,GFSLSTSGMGIWWDGDEARNRYDPPWFVD,0.0,0,jain2017_pnas
girentuximab,GFTFSNYYINSDGGITARHRSGYFSMDY,0.0,0,jain2017_pnas
glembatumumab,GGSISSFNYYIYYSGSTARGYNWNYFDY,0.0,0,jain2017_pnas
golimumab,GFIFSSYAMSYDGSNKARDRGIAAGGNYYYYGMDV,,1,jain2017_pnas
guselkumab,GYSFSNYWIDPSNSYTARWYYKPFDV,,1,jain2017_pnas
ibalizumab,GYTFTSYVINPYNDGTAREKDNYATGAWFAY,0.0,0,jain2017_pnas
imgatuzumab,GFTFTDYKFNPNSGYSARLSPGGYYVMDA,1.0,5,jain2017_pnas
infliximab,GFIFSNHWIRSKSINSATSRNYYGSTYDY,0.0,0,jain2017_pnas
inotuzumab,GYRFTNYWINPGNNYATREGYGNYGAWFAY,,3,jain2017_pnas
ipilimumab,GFTFSSYTISYDGNNKARTGWLGPFDY,0.0,0,jain2017_pnas
ixekizumab,GYSFTDYHINPMYGTTARYDYFTGTGVY,1.0,6,jain2017_pnas
lampalizumab,GYTFTNYGINTYTGETEREGGVNN,0.0,0,jain2017_pnas
lebrikizumab,GFSLSAYSIWGDGKIAGDGYYPYAMDN,0.0,0,jain2017_pnas
lenzilumab,GYSFTNYYINAGNGNTVRRQRFPYYFDY,1.0,6,jain2017_pnas
lintuzumab,GYTFTDYNIYPYNGGTARGRPAMDY,0.0,0,jain2017_pnas
lirilumab,GGTFSFYAFIPIFGAAARIPSGSYYYDYDMDV,0.0,0,jain2017_pnas
lumiliximab,GFRFTFNNYYISSSGDPTASLTTGSDS,0.0,0,jain2017_pnas
matuzumab,GYTFTSHWFNPSNGRTASRDYDYDGRYFDY,0.0,0,jain2017_pnas
mavrilimumab,GYTLTELSFDPEENEIAIVGSFSPLTLGL,0.0,0,jain2017_pnas
mepolizumab,GFSLTSYSIWASGGTARDPPSSLLRLDY,0.0,0,jain2017_pnas
mogamulizumab,GFIFSNYGISSASTYSGRHSDGNFAFGY,0.0,0,jain2017_pnas
motavizumab,GFSLSTAGMSIWWDDKKARDMIFNFYFDV,,1,jain2017_pnas
muromonab,GYTFTRYTINPSRGYTARYYDDHYCLDY,0.0,0,jain2017_pnas
natalizumab,GFNIKDTYIDPANGYTAREGYYGNYGVYAMDY,0.0,0,jain2017_pnas
necitumumab,GGSISSGDYYIYYSGSTARVSIFGVGTFDY,0.0,0,jain2017_pnas
nimotuzumab,GYTFTNYYINPTSGGSTRQGLWFDSDGRGFDF,0.0,0,jain2017_pnas
nivolumab,GITFSNSGIWYDGSKRATNDDY,0.0,0,jain2017_pnas
obinutuzumab,GYAFSYSWIFPGDGDTARNVFDGYWLVY,0.0,0,jain2017_pnas
ocrelizumab,GYTFTSYNIYPGNGDTARVVYYSNSYWYFDV,0.0,0,jain2017_pnas
ofatumumab,GFTFNDYAISWNSGSIAKDIQYGNYYYGMDV,0.0,0,jain2017_pnas
olaratumab,GGSINSSSYYFFYTGSTARQSTYYYGSGNYYGWFDR,0.0,0,jain2017_pnas
olokizumab,GFNFNDYFMRNKNYQYGTARESYYGFTSY,0.0,0,jain2017_pnas
omalizumab,GYSITSGYSITYDGSTARGSHYFGHWHFAV,0.0,0,jain2017_pnas
onartuzumab,GYTFTSYWIDPSNSDTATYRSYVTPLDY,0.0,0,jain2017_pnas
otelixizumab,GFTFSSFPISTSGGRTAKFRQYSGGFDY,0.0,0,jain2017_pnas
otlertuzumab,GYSFTGYNIDPYYGGTARSVGPFDS,0.0,0,jain2017_pnas
ozanezumab,GYTFTSYWINPSNGGTELMQGY,,3,jain2017_pnas
palivizumab,GFSLSTSGMSIWWDDKKARSMITNWYFDV,0.0,0,jain2017_pnas
panitumumab,GGSVSSGDYYIYYSGNTVRDRVTGAFDI,0.0,0,jain2017_pnas
panobacumab,GFTFSPYWINSDGSTARDRYYGPEM,0.0,0,jain2017_pnas
parsatuzumab,GYTFIDYYINLDNSGTAREGVYHDYDDYAMDY,1.0,6,jain2017_pnas
patritumab,GGSFSGYYINHSGSTARDKWTWYFDL,1.0,4,jain2017_pnas
pembrolizumab,GYTFTNYYINPSNGGTARRDYRFDMGFDY,0.0,0,jain2017_pnas
pertuzumab,GFTFTDYTVNPNSGGSARNLGPSFYFD,0.0,0,jain2017_pnas
pinatuzumab,GYEFSRSWIYPGDGDTARDGSSWDWYFDV,0.0,0,jain2017_pnas
polatuzumab,GYTFSSYWILPGGGDTTRRVPIRLDY,0.0,0,jain2017_pnas
ponezumab,GYYTEAYYIDPATGNTASLYSLPVY,1.0,4,jain2017_pnas
radretumab,GFTFSSFSISGSSGTTAKPFPYFDY,0.0,0,jain2017_pnas
ramucirumab,GFTFSSYSISSSSSYIARVTDAFDI,0.0,0,jain2017_pnas
ranibizumab,GYDFTHYGINTYTGEPAKYPYYYGTSHWYFDV,,1,jain2017_pnas
reslizumab,GLSLTSNSIWSNGDTAREYYGYFDY,0.0,0,jain2017_pnas
rilotumumab,GGSISIYYVYYSGSTARGGYDFWSGYFDY,0.0,0,jain2017_pnas
rituximab,GYTFTSYNIYPGNGDTARSTYYGGDWYFNV,0.0,0,jain2017_pnas
robatumumab,GFTFSSFAIDTRGATARLGNFYYGMDV,1.0,4,jain2017_pnas
romosozumab,GYTFTDYNINPNSGGAARLGYDDIYDDWYFDV,0.0,0,jain2017_pnas
sarilumab,RFTFDDYAISWNSGRIAKGRDSFDI,0.0,0,jain2017_pnas
secukinumab,GFTFSNYWINQDGSEKVRDYYDILTDYYIHYWYFDL,0.0,0,jain2017_pnas
seribantumab,GFTFSHYVISSSGGWTTRGLKMATIFDY,0.0,0,jain2017_pnas
sifalimumab,GYTFTSYSISVYNGNTARDPIAAGY,,3,jain2017_pnas
siltuximab,GFTFSSFAISSGGSYTARGLWGYYALDY,0.0,0,jain2017_pnas
simtuzumab,GYAFTYYLINPGSGGTARNWMNFDY,1.0,6,jain2017_pnas
sirukumab,GFTFSPFAISPGGSWTARQLWGYYALDI,1.0,5,jain2017_pnas
tabalumab,GGSFSGYYINHSGSTARGYYDILTGYYYYFDY,0.0,0,jain2017_pnas
tanezumab,GFSLIGYDIWGDGTTARGGYWYATSYYFDY,,1,jain2017_pnas
teplizumab,GYTFTRYTINPSRGYTARYYDDHYCLDY,,2,jain2017_pnas
tigatuzumab,GFTFSSYVISSGGSYTARRGDSMITTDY,0.0,0,jain2017_pnas
tildrakizumab,GYIFITYWIFPASGSAARGGGGFAY,0.0,0,jain2017_pnas
tocilizumab,GYSITSDHAISYSGITARSLARTTAMDY,0.0,0,jain2017_pnas
tovetumab,GFTFSDYYISSSGSIIAREGRIAARGMDV,0.0,0,jain2017_pnas
tralokinumab,GYTFTNYGISANNGDTARDSSSSWARWFFDL,0.0,0,jain2017_pnas
trastuzumab,GFNIKDTYIYPTNGYTSRWGGDGFYAMDY,0.0,0,jain2017_pnas
tremelimumab,GFTFSSYGIWYDGSNKARDPRGATLYYYYYGMDV,0.0,0,jain2017_pnas
urelumab,GGSFSGYYINHGGYVARDYGPGNYDWYFDL,0.0,0,jain2017_pnas
ustekinumab,GYSFTTYWMSPVDSDIARRRPGQGYFDF,,3,jain2017_pnas
vedolizumab,GYTFTSYWIDPSESNTARGGYDGWDYAIDY,0.0,0,jain2017_pnas
veltuzumab,GYTFTSYNIYPGMGDTARSTYYGGDWYFDV,0.0,0,jain2017_pnas
visilizumab,GYTFISYTINPRSGYTARSAYYDYDGFAY,,3,jain2017_pnas
zalutumumab,GFTFSTYGIWDDGSYKARDGITMVRGVMKDYFDY,,1,jain2017_pnas
zanolimumab,GGSFSGYYINHSGSTARVINWFDP,0.0,0,jain2017_pnas
